KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Current Investments (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Cash & Current Investments for 8 consecutive years, with $167.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 15.95% year-over-year to $167.9 million, compared with a TTM value of $167.9 million through Dec 2025, up 15.95%, and an annual FY2025 reading of $167.9 million, up 15.95% over the prior year.
  • Cash & Current Investments was $167.9 million for Q4 2025 at Esperion Therapeutics, up from $92.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $259.3 million in Q4 2021 and bottomed at $82.2 million in Q4 2023.
  • Average Cash & Current Investments over 5 years is $161.2 million, with a median of $164.6 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments soared 82.63% in 2022, then crashed 54.54% in 2025.
  • Year by year, Cash & Current Investments stood at $259.3 million in 2021, then plummeted by 35.66% to $166.9 million in 2022, then crashed by 50.71% to $82.2 million in 2023, then surged by 76.01% to $144.8 million in 2024, then grew by 15.95% to $167.9 million in 2025.
  • Business Quant data shows Cash & Current Investments for ESPR at $167.9 million in Q4 2025, $92.4 million in Q3 2025, and $86.1 million in Q2 2025.